Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $120 to $205.
Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $120 to $205.